Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Perspective

Predicting Enhanced Cell Killing through PARP Inhibition

Julie K. Horton and Samuel H. Wilson
Julie K. Horton
Laboratory of Structural Biology, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel H. Wilson
Laboratory of Structural Biology, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1541-7786.MCR-12-0512 Published January 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    A, scheme of pol β-dependent BER initiated by a monofunctional (left) or bifunctional (right) DNA glycosylase showing formation of 5′- or 3′-blocking groups (circled), respectively, in repair intermediates. The specific interaction between PARP-1 and the 5′-dRP–containing intermediate is indicated. B, inhibitory effect of 4-AN (10 μmol/L) on PAR synthesis in MMS-treated mouse embryonic fibroblasts (MEF; 10 mmol/L for 20 minutes at 4°C) as measured by a commercial ELISA assay (Trevigen). C, sensitivity of wild-type MEFs to a 1-hour exposure to MMS (circles) and the sensitization obtained by cotreatment with 4-AN (10 μmol/L for 24 hours; squares). D, sensitivity of wild-type mouse fibroblasts to a 1-hour exposure to peroxynitrite (circles) and the absence of sensitization provided by cotreatment with 4-AN (10 μmol/L for 24 hours; squares). The plot was drawn to the same scale as in C. Cell sensitivity was obtained by growth inhibition assays as described previously (12). E, comparison of 4-AN–mediated fold-sensitization of wild-type MEFs to MMS (40-fold) and peroxynitrite (negligible).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    A, hypersensitivity (3.2-fold) of pol β–null mouse fibroblasts (open symbols) to TMZ (4-hour exposure). B, sensitization to TMZ cytotoxicity by 24-hour exposure to the PARP inhibitor 4-AN (squares). C, comparison of 4-AN–mediated sensitization in wild-type and pol β–null MEFs to agents resulting in damage repaired by monofunctional and bifunctional BER pathways. D, low-level sensitization by 4-AN of pol β–null cells to peroxynitrite.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Level of hypersensitivity of pol β–null MEFs (open circles) to exposure to (A) cisplatin (1 hour); (B) Ara C (24 hours) or (C) camptothecin (24 hours) compared with wild-type MEFs (closed circles). A to C, sensitization of pol β–null (open squares) and wild-type MEFs (closed squares) by 24-hour exposure to 4-AN (10 μmol/L). D, comparison of 4-AN–mediated sensitization to TMZ and other types of clinically used DNA-damaging agents in wild-type and pol β–null mouse fibroblasts.

PreviousNext
Back to top
Molecular Cancer Research: 11 (1)
January 2013
Volume 11, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Predicting Enhanced Cell Killing through PARP Inhibition
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Predicting Enhanced Cell Killing through PARP Inhibition
Julie K. Horton and Samuel H. Wilson
Mol Cancer Res January 1 2013 (11) (1) 13-18; DOI: 10.1158/1541-7786.MCR-12-0512

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Predicting Enhanced Cell Killing through PARP Inhibition
Julie K. Horton and Samuel H. Wilson
Mol Cancer Res January 1 2013 (11) (1) 13-18; DOI: 10.1158/1541-7786.MCR-12-0512
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Background on DNA Base Excision Repair
    • Binding of PARP-1 to Intermediates of BER
    • PARP Inhibition and Cellular Hypersensitivity to DNA Damage
    • Influence of Pol β Expression on the Effect of PARP Inhibition
    • Summary of 4-AN–Mediated Sensitization to Other Agents
    • Concluding Remarks: Perspective on Predicting PARP Inhibitor Sensitization
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Calcium in MEN1 Gastrinoma Pathogenesis
  • Type-I IFN in AML
  • Drosophila as a Model for Antioxidants Effects on Cancer
Show more Perspective
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement